1
Masataka Konishi, Kyoichiro Saitoh, Hiroaki Ohkuma, Hiroshi Kawaguchi: BBM-1675, a new antibiotic complex. Bristol Myers Company, David M Morse, June 23, 1987: US04675187 (55 worldwide citation)

A novel antibiotic complex designated herein as BBM-1675 complex is produced by fermentation of certain novel strains of Actinomadura verrucosospora. The complex may be separated into two major components, BBM-1675 A.sub.1 and A.sub.2, and four minor components, BBM-1675 A.sub.3, A.sub.4, B.sub.1 an ...


2

3
Terrence J Murray, Bhiku G Patel, Richard O Muhlhauser: High oil phase pharmaceutical vehicles and sunscreen compositions having waterproof sun protection factors. Bristol Myers Company, David M Morse, March 7, 1989: US04810489 (40 worldwide citation)

High oil phase pharmaceutical vehicles in the form of an emulsion system having an oil phase content of from about 35% to about 65%, wherein the emulsion system comprises from about 1% to about 10% of an alkylated PVP copolymer, from about 2% to about 10% of an emulsifier, and a solvent system. The ...


4
Peter F Juby: Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides. Bristol Myers Company, David M Morse, June 24, 1980: US04209623 (40 worldwide citation)

A series of 1,6-dihydro-6-oxo-2-phenylpyrimidine-5-N-(1H-tetrazol-5-yl)carboxamides is provided for use as inhibitors of allergic reactions. The compounds show antiallergy activity by both oral and parenteral routes of administration.


5
Takushi Kaneko, Henry S Wong, Jacob J Utzig: Rebeccamycin analogs. Bristol Myers Company, David M Morse, November 15, 1988: US04785085 (35 worldwide citation)

There are disclosed analogs of the antitumor agent, rebeccamycin, which possess antineoplastic properties against mammalian, particularly experimental animal, tumor systems. The compounds of the invention are aminoalkylated derivatives of rebeccamycin produced by first reacting rebeccamycin with a s ...


6
Ismat Ullah, Gary J Wiley: Enteric coated pharmaceutical tablet and method of manufacturing. Bristol Myers Squibb Company, Scott Alexander McNeil, David M Morse, Burton Rodney, May 27, 2003: US06569457 (34 worldwide citation)

A high drug load enteric coated pharmaceutical composition is provided which includes a core in the form of a tablet and which is comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, and having an enteric coating formed of methacrylic acid copolymer and a ...


7
Marcel Menard, Alain Martel: Antibacterial agents, and 4-thio azetidinone intermediates. Bristol Myers Company, David M Morse, June 9, 1981: US04272437 (33 worldwide citation)

This invention relates to 2-substituted and 2,6-disubstituted penem compounds of the formula ##STR1## wherein Y is hydrogen, halo or certain organic substituents and X represents certain organic substituents. Also included in the invention are pharmaceutically acceptable salts of the above compounds ...


8
Peter Frederick Juby: 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones. Bristol Myers Company, David M Morse, October 24, 1978: US04122274 (32 worldwide citation)

A novel series of optionally substituted 3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-ones is provided for use as inhibitors of allergic reactions. The compounds exhibit antiallergy activity by both oral and parenteral routes of administration.


9
Takushi Kaneko, Henry S Wong, Jacob J Utzig: Rebeccamycin derivative containing pharmaceutical composition. Bristol Myers Company, David M Morse, February 28, 1989: US04808613 (31 worldwide citation)

There are disclosed analogs of the antitumor agent, rebaccamycin, which possess antineoplastic properties against mammalian, particularly experimental animal, tumor systems. The compounds of the invention are aminoalkylated derivatives of rebeccamycin produced by first reacting rebeccamycin with a s ...


10
Daniel Bouzard, Abraham Weber, Jacques Stemer: Cephadroxil monohydrate. Bristol Myers Company, Robert E Carnahan, David M Morse, March 12, 1985: US04504657 (26 worldwide citation)

A novel crystalline monohydrate of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-methyl-3-cephem-4 -carboxylic acid is prepared and found to be a stable useful form of the cephalosporin antibiotic especially advantageous for pharmaceutical formulations.



Click the thumbnails below to visualize the patent trend.